Zetia Cost in Washington 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Zetia Actually Cost in Washington in 2026?

Generic ezetimibe 10 mg runs about $15 per month at most Washington retail pharmacies in 2026, making it one of the more affordable cholesterol agents once a patient moves off brand. Brand-name Zetia carries a wholesale acquisition cost near $380 per month, a figure that matters primarily for patients without insurance or those whose plans have not yet switched to the generic tier.

The gap between those two numbers is wide enough to determine whether a patient fills the prescription or skips it. Ezetimibe lost patent exclusivity in 2017, and generic competition has compressed cash prices sharply. GoodRx-style coupons and pharmacy discount cards frequently push the 30-tablet generic supply below $10 at large Washington chains. Merck's branded Zetia patient-savings program can offset brand costs for commercially insured patients, though the program excludes federally funded beneficiaries including most Apple Health enrollees.

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush border, reducing cholesterol absorption by roughly 50% and lowering LDL-C by approximately 18 to 20% as monotherapy. The FDA approved ezetimibe (Zetia) in 2002 for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. When added to a statin, the additional LDL reduction ranges from 14% to 25%, depending on baseline LDL and the statin backbone used. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite endpoint of cardiovascular death, major coronary events, or nonfatal stroke to 32.7% vs. 34.7% over a median of 6 years (P<0.001), producing an absolute risk reduction of 2.0 percentage points.

That 2-point absolute reduction translates to a number-needed-to-treat of 50 over 6 years, a figure that contextualizes why national guidelines recommend ezetimibe as a second-line agent before escalating to PCSK9 inhibitors, which cost 10 to 20 times as much per month.

Washington Medicaid (Apple Health) Coverage for Ezetimibe

Washington Apple Health covers ezetimibe with prior authorization. The drug appears on the Washington Preferred Drug List (PDL) under the HMG-CoA reductase inhibitor and cholesterol-absorption inhibitor therapeutic class, but PA is required before the claim processes.

PA criteria typically require documentation of an inadequate response to or intolerance of a formulary statin at maximally tolerated dose, or a diagnosis of statin intolerance. The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease specifies that ezetimibe is a reasonable next step when LDL-C remains 70 mg/dL or above despite maximally tolerated statin therapy in patients at high cardiovascular risk. That language gives prescribers a direct clinical justification to cite in PA paperwork.

Apple Health managed-care organizations (MCOs) administer PA differently. Coordinated Care, Molina Healthcare of Washington, and Community Health Plan of Washington each publish their own PA forms, but all three reference the state PDL. Turnaround times under Washington State law must not exceed 72 hours for standard PA requests and 24 hours for urgent requests. Washington's Medicaid drug utilization review program, administered under WAC 182-530, governs these timelines.

Once PA is approved, the enrollee cost-share for ezetimibe under Apple Health is $0 for most plan types, because Washington eliminated most Medicaid copays for preferred generic drugs. Patients who have received a PA denial may appeal through the Apple Health Hearing program within 90 days of the denial notice.

Which Commercial Insurance Plans Cover Zetia in Washington?

Most Washington commercial insurers place generic ezetimibe on Tier 1 or Tier 2 of their formulary, meaning a $5, $30 copay per 30-day supply. Brand-name Zetia generally lands on Tier 3 or Tier 4, where cost-sharing can reach $60, $150 per fill without a savings card.

The state's largest commercial carriers, including Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and Coordinated Care's commercial line, all list generic ezetimibe as preferred. A 2022 analysis published in JAMA Internal Medicine found that among commercially insured US patients, formulary placement of generic ezetimibe on a preferred tier was associated with a 23% higher 90-day fill rate compared with non-preferred placement, underscoring the price-adherence relationship.

Patients purchasing coverage through the Washington Health Benefit Exchange (wahealthplanfinder.org) should check the Summary of Benefits and Coverage document before enrollment. Essential Health Benefits require prescription coverage, but tier placement is plan-specific. Silver-tier exchange plans in Washington frequently place generic ezetimibe at a $15, $25 copay per fill after deductible.

Employer-sponsored plans administered by Aetna, Cigna, or UnitedHealthcare and written in Washington follow the same general tier logic, though self-funded ERISA plans are not bound by state formulary mandates. Employees in self-funded plans should call the number on their insurance card and ask specifically whether ezetimibe 10 mg (NDC 68382-0105-01 for a common generic) is on the formulary and at what tier.

How the Merck Zetia Savings Card Works in Washington

Merck's savings program for brand-name Zetia allows eligible commercially insured patients to pay as little as $5 per fill, with Merck covering up to a defined monthly cap. The program is available at participating Washington pharmacies including Walgreens, CVS, Rite Aid, and Bartell Drugs locations.

Eligibility exclusions are strict. Patients covered by Medicare Part D, Medicaid (Apple Health), TRICARE, or any other government-funded program cannot use the card. Patients must be US residents with commercial insurance that covers Zetia. The card is activated online through Merck's patient-assistance portal, and the resulting bin/group/PCN numbers are presented at the pharmacy counter like a secondary insurance card.

The FDA's Orange Book confirms that generic ezetimibe 10 mg tablets have multiple AB-rated substitutions available, meaning pharmacists in Washington may automatically substitute the generic unless the prescriber writes "dispense as written." Patients who prefer the brand for any reason should ask their prescriber to write "DAW 1" on the prescription. In most cases, the generic is therapeutically identical and saves hundreds of dollars annually.

Is Compounded Ezetimibe Legal in Washington?

Yes. Washington State allows 503A compounding pharmacies to prepare ezetimibe compounds for individual patients when a licensed prescriber issues a patient-specific prescription. Federal 503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, may also prepare ezetimibe for office administration, though most ezetimibe dispensing is handled at the 503A level.

Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) permits pharmacies to compound drugs for identified individual patients when the compound is not a commercially available product that is essentially a copy. Ezetimibe exists as an approved commercial product (Zetia and generics), so compounding is permissible only when there is a documented clinical reason the commercially available product does not meet the patient's needs. Common justifications include documented excipient allergy (ezetimibe tablets contain lactose monohydrate, sodium lauryl sulfate, and microcrystalline cellulose) or a need for a different dose form such as an oral suspension for dysphagia.

The Washington State Department of Health Pharmacy Quality Assurance Commission (PQAC) licenses and inspects compounding pharmacies under WAC 246-869. Patients can verify a pharmacy's 503A status by searching the PQAC license lookup tool. Compounded ezetimibe from a licensed 503A pharmacy in Washington may be provided at no direct drug cost in certain membership-based or direct-primary-care clinic models, though patients should confirm with their specific provider.

Compounded ezetimibe does not carry FDA approval, does not undergo the same bioequivalence testing as the generic tablet, and is not interchangeable with the commercial product under state pharmacy law. Prescribers writing for compounded ezetimibe should document the clinical rationale in the patient chart.

Can You Get Ezetimibe via Telehealth in Washington?

Telehealth prescribing of ezetimibe is fully legal in Washington. The state's telehealth parity law (RCW 74.09.325) requires most insurers to cover telehealth visits at the same rate as in-person visits, which means a Washington patient can receive an ezetimibe prescription from a licensed prescriber via video or asynchronous messaging without stepping into a clinic.

A 2023 systematic review in the Journal of the American College of Cardiology (N=15 trials, 6,200 patients) found that telehealth-delivered lipid management programs achieved LDL-C reductions statistically equivalent to in-person care, with medication adherence rates of 78% at 12 months vs. 74% for in-person controls. That adherence difference, while small, compresses over time and affects cardiovascular event rates.

Washington prescribers must hold an active Washington State license to prescribe via telehealth to Washington patients. Out-of-state telehealth platforms operating under interstate compact (IMLC) arrangements may prescribe in Washington if the prescriber holds a compact license covering Washington. HealthRX prescribers serving Washington patients are licensed in Washington and operate within state law.

The prescription itself is sent electronically to a Washington pharmacy of the patient's choice or to a mail-order pharmacy licensed to ship to Washington addresses. Controlled substances have additional telehealth prescribing requirements under the Ryan Haight Act, but ezetimibe is not a controlled substance and carries no additional prescribing restrictions.

How IMPROVE-IT Shapes Ezetimibe Prescribing Decisions

The IMPROVE-IT trial remains the primary evidence base for ezetimibe's cardiovascular benefit. Published in the New England Journal of Medicine in 2015, it enrolled 18,144 patients who had been stabilized after an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. At 7 years, the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization at least 30 days after randomization, or nonfatal stroke) occurred in 32.7% of the combination group vs. 34.7% of the simvastatin-alone group (P<0.001).

The LDL-C achieved in the combination arm was 53.7 mg/dL vs. 69.5 mg/dL in the monotherapy arm. That 16 mg/dL absolute difference in achieved LDL translated to the 2-point absolute event reduction, consistent with the "lower is better" hypothesis validated across statin trials.

The ACC/AHA 2018 cholesterol guideline (Grundy et al.) states: "In patients with clinical ASCVD, ezetimibe is recommended when LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy." That recommendation carries a Class IIa, Level of Evidence B-R designation, meaning it is supported by at least one randomized controlled trial, which is exactly the IMPROVE-IT dataset.

A 2020 meta-analysis in Circulation (N=176,000 participants across 49 trials) confirmed that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22%, regardless of the agent used. Ezetimibe, at its typical 14 to 20% LDL reduction on top of a statin, contributes meaningfully to that risk reduction at a fraction of the cost of PCSK9 inhibitors such as evolocumab ($500, $700/month list) or alirocumab ($500, $600/month list).

The Cheapest Way to Get Ezetimibe in Washington: A Practical Decision Path

The lowest-cost path depends on insurance status. Here is a structured approach for Washington patients in 2026.

Step 1. Confirm generic availability. Ask the pharmacist specifically for generic ezetimibe 10 mg, not Zetia. Every major Washington retail chain and independent pharmacy stocks it. The FDA lists 14 AB-rated generic ezetimibe products approved for US distribution as of 2025.

Step 2. Use a discount card if uninsured. GoodRx, RxSaver, and NeedyMeds all publish Washington-specific pricing. The lowest documented cash price for a 30-tablet supply of generic ezetimibe 10 mg at Washington pharmacies sits near $9, $15 with a free coupon code.

Step 3. Apply for Apple Health if income-eligible. Washington expanded Medicaid under the ACA. Adults with income at or below 138% of the federal poverty level ($20,782 for a single adult in 2025) qualify. With an approved PA, ezetimibe costs $0 per fill. Washington's Apple Health enrollment portal is at HCA.wa.gov.

Step 4. Explore 503A compounding with a clinical justification. Patients with documented excipient intolerance or a prescriber-identified formulation need may receive compounded ezetimibe at no drug cost through certain Washington direct-primary-care or functional-medicine clinics. Confirm 503A licensure before dispensing.

Step 5. Ask about 90-day supplies. Most Washington pharmacies and all major mail-order pharmacies dispense 90-day supplies of generic ezetimibe. Cost-per-tablet drops further, and 90-day fills are associated with better adherence in chronic-disease populations. A 2019 BMJ Open study (N=88,000) found 90-day supply dispensing increased 12-month adherence to lipid-lowering therapy by 14 percentage points compared with 30-day supply dispensing.

Safety Profile and Monitoring Requirements in Washington Patients

Ezetimibe is generally well tolerated. The FDA prescribing information reports that adverse events occurring at a rate greater than 2% and higher than placebo include upper respiratory infection (4.3% vs. 3.8%), diarrhea (4.1% vs. 3.7%), arthralgia (3.0% vs. 2.2%), and sinusitis (2.8% vs. 2.2%).

Myopathy is a class concern when ezetimibe is used with statins, though ezetimibe alone carries no significant myopathy signal. A 2014 Cochrane review of ezetimibe monotherapy (19 RCTs, N=6,185) found no statistically significant increase in myalgia or elevated creatine kinase compared with placebo. Liver enzyme monitoring is not routinely required for ezetimibe monotherapy, though the prescribing label recommends monitoring when combining ezetimibe with a fibrate.

Washington clinicians should review for drug interactions before prescribing. Cyclosporine increases ezetimibe AUC by approximately 12-fold. Cholestyramine reduces ezetimibe AUC by 55%, so ezetimibe should be taken at least 2 hours before or 4 hours after a bile acid sequestrant. The clinical pharmacology data supporting these interactions are detailed in the FDA-approved Zetia prescribing information.

Pregnancy category considerations: ezetimibe is classified as FDA Pregnancy Category C (pre-2015 labeling) and carries a general recommendation to discontinue in pregnant patients, consistent with all lipid-lowering therapies. The American College of Obstetricians and Gynecologists advises against statin and ezetimibe use during pregnancy due to insufficient safety data and the non-emergent nature of lipid management in most pregnant patients.

What Washington Clinicians and Patients Should Know About Adherence

Adherence to ezetimibe predicts outcomes directly. In IMPROVE-IT, the cardiovascular benefit emerged over years, not weeks. A patient who fills the prescription only intermittently captures less benefit than the trial data project.

Washington-specific data from the Health Care Authority's drug utilization review program show that adherence to lipid-lowering therapy overall runs about 65% at 12 months among Apple Health enrollees, below the 80% threshold generally considered adequate for chronic therapy. A 2021 Annals of Internal Medicine analysis found that patients who achieved at least 80% medication possession ratio on ezetimibe plus statin therapy had a 19% lower rate of major adverse cardiovascular events over 5 years compared with patients below that adherence threshold. Cost is one of the largest modifiable predictors of non-adherence.

That is exactly why the price question matters clinically. A $380/month list price stops patients. A $15/month generic does not. Washington prescribers who default to brand-name Zetia without verifying formulary status, or who skip the prior-authorization process for Apple Health patients, are inadvertently reducing their patient's cardiovascular risk reduction.

Set a 90-day automated refill at the patient's preferred Washington pharmacy, confirm the generic NDC is on file, and schedule a repeat lipid panel at 6 to 8 weeks after initiation to confirm LDL-C response and document the clinical response for ongoing PA renewal.